Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Thomas Triomphe

Thomas Triomphe

Executive Vice President, Vaccines, Sanofi

Appears in 1 story

Notable Quotes

"This acquisition enhances Sanofi's adult immunization presence and brings new options to our portfolio."

"We now have probably the largest number of vaccine platforms in the industry."

Stories

Big Pharma's vaccine land grab

Money Moves

Leading Sanofi's vaccine expansion strategy

Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.

Updated 2 hours ago